Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18708181 | 1.00 | ADORA2A (0.47) | ADORA2AADORA3ADORA1P2RY12TSHR | |
| SCHEMBL18708183 | 0.88 | BMPR1B (0.43) | ADORA1P2RY12TSHR | |
| SCHEMBL18503744 | 0.88 | BMPR1B (0.43) | ADORA1P2RY12TSHR | |
| SCHEMBL18513223 | 0.85 | PRMT6 (0.40) | ADORA2AADORA3ADORA1P2RY12 | |
| SCHEMBL18708182 | 0.83 | P2RY12 (0.38) | P2RY12 | |
| SCHEMBL18503746 | 0.83 | P2RY12 (0.38) | P2RY12 | |
| SCHEMBL18708184 | 0.83 | AHCY (0.47) | ADORA2AADORA3ADORA1P2RY12TSHR | |
| SCHEMBL18503740 | 0.83 | AHCY (0.47) | ADORA2AADORA3ADORA1P2RY12TSHR | |
| SCHEMBL18503743 | 0.82 | ADORA1 (0.43) | ADORA2AADORA3ADORA1P2RY12TSHR | |
| SCHEMBL18513219 | 0.82 | ADORA1 (0.43) | ADORA2AADORA3ADORA1P2RY12TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044528-A1 | CROSSLINKED NUCLEOSIDE AND NUCLEOTIDE | OSAKA UNIVERSITY (JP) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044528-A1 | CROSSLINKED NUCLEOSIDE AND NUCLEOTIDE | NSUN2, NCL, NSUN3 | ADORA2A 226/4885ADORA3 310/4885ADORA1 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.